Small Caps
Shield's Feraccru gets registration in Australia
Commercial-stage pharmaceutical company Shield Therapeutics said on Tuesday that Australia's Therapeutics Goods Administration (TGA) has registered ‘Feraccru’ in the country’s Register of Therapeutic Goods, to treat iron deficiency with or without anaemia in adults.
Condor Gold upbeat on latest data from La India drilling
Condor Gold announced on Tuesday that the first 26 drill holes for a combined 1,296 metres of diamond drill core had been completed on La India starter pit infill drilling programme.
President Energy realigns Rio Negro drilling programme
South America-focussed President Energy updated the market on its drilling programme in Argentina’s Rio Negro province on Tuesday, reporting that a drilling rig had been contracted, with site preparations in progress.
Science Group reports record revenue, operating profit
Science Group reported record revenue and adjusted operating profit, ahead of upgraded expectations, in its 2020 results on Tuesday.
Victoria to issue another EUR 250m in senior secured notes
Flooring company Victoria said on Tuesday that, following the “very favourable” reception of its recent senior secured note offering on 23 February, it now intended to offer €250m (£214. 44m) in senior secured notes due 2028.
Midwich delivers record revenue performance, profits fall
Specialist audio visual distributor Midwich reported a record revenue performance in its full-year results on Tuesday, as its turnover improved 3. 7% year-on-year to £711. 8m, despite the challenges arising from the Covid-19 pandemic.
Ideagen buys compliance software firm Qualtrax in $14.9m deal
Regulatory and compliance software company Ideagen announced the acquisition of Qualtrax on Tuesday, to further extend its presence in the United States, for net cash of $14. 9m (£10. 73m).
CareTech trading in line as it navigates Covid and lockdowns
Social care and education services provider CareTech said on Tuesday that its trading in 2021 to-date was in-line with its and the market's expectations, and it had successfully maintained its “proactive approach” to managing the impact of the Covid-19 pandemic.
Avacta enters licence deal with Werfen subsidiary Biokit
Cancer therapy and diagnostics developer Avacta has entered into a licence agreement with Werfen subsidiary Biokit, it announced on Tuesday, to incorporate ‘Affimer’ reagents into a Biokit in-vitro diagnostic product.